Gato Sheila, Lucena-Valera Ana, Muñoz-Hernández Rocío, Sousa José Manuel, Romero-Gómez Manuel, Ampuero Javier
SeLiver Group, Instituto de Biomedicina de Sevilla, Sevilla 41013, Spain.
Digestive Department, Hospital Universitario Virgen del Rocio, Sevilla 41013, Spain.
World J Virol. 2021 Nov 25;10(6):301-311. doi: 10.5501/wjv.v10.i6.301.
Coronavirus disease 2019 (COVID-19) has caused a global pandemic unprecedented in over a century. Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a predominantly respiratory infection, various degrees of liver function abnormalities have been reported. Pre-existing liver disease in patients with SARS-CoV-2 infection has not been comprehensively evaluated in most studies, but it can critically compromise survival and trigger hepatic decompensation. The collapse of the healthcare services has negatively impacted the diagnosis, monitoring, and treatment of liver diseases in non-COVID-19 patients. In this review, we aim to discuss the impact of COVID-19 on liver disease from the experimental to the clinic perspective.
2019年冠状病毒病（COVID-19）引发了一场一个多世纪以来前所未有的全球大流行。尽管严重急性呼吸综合征冠状病毒2（SARS-CoV-2）主要是一种呼吸道感染，但已有报告称存在不同程度的肝功能异常。大多数研究尚未全面评估SARS-CoV-2感染患者的既往肝病情况，但它可能严重影响生存并引发肝失代偿。医疗服务的崩溃对非COVID-19患者肝病的诊断、监测和治疗产生了负面影响。在本综述中，我们旨在从实验到临床的角度讨论COVID-19对肝病的影响。
